Cargando…

SGLT‐2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects

Detalles Bibliográficos
Autores principales:	Lam, Carolyn S. P., Chandramouli, Chanchal, Ahooja, Vineeta, Verma, Subodh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Contemporary Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818035/ https://www.ncbi.nlm.nih.gov/pubmed/31607208 http://dx.doi.org/10.1161/JAHA.119.013389

Ejemplares similares

Small‐Vessel Disease in the Heart and Brain: Current Knowledge, Unmet Therapeutic Need, and Future Directions
por: Berry, Colin, et al.
Publicado: (2019)

Current Landscape of Heart Failure Gene Therapy
por: Kieserman, Jake M., et al.
Publicado: (2019)

Therapeutic Stalemate in Heart Failure With Preserved Ejection Fraction
por: Samson, Rohan, et al.
Publicado: (2021)

Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
por: De Nicola, Luca, et al.
Publicado: (2022)

Maternal Heart Failure
por: Bright, Rachel A., et al.
Publicado: (2021)

The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction
por: Greene, Stephen J., et al.
Publicado: (2013)

Clinical implications of the universal definition for the prevention and treatment of heart failure
por: Chandramouli, Chanchal, et al.
Publicado: (2022)

Role of Monocytes in Heart Failure and Atrial Fibrillation
por: Shahid, Farhan, et al.
Publicado: (2018)

Glucose Metabolism in Cardiac Hypertrophy and Heart Failure
por: Tran, Diem H., et al.
Publicado: (2019)

Role of Volume Redistribution in the Congestion of Heart Failure
por: Fudim, Marat, et al.
Publicado: (2017)

Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction
por: Samson, Rohan, et al.
Publicado: (2016)

Molecular, Cellular, and Clinical Evidence That Sodium‐Glucose Cotransporter 2 Inhibitors Act as Neurohormonal Antagonists When Used for the Treatment of Chronic Heart Failure
por: Packer, Milton
Publicado: (2020)

Glucose Metabolism in the Kidney: Neurohormonal Activation and Heart Failure Development
por: Gronda, Edoardo, et al.
Publicado: (2020)

Fluid Volume Homeostasis in Heart Failure: A Tale of 2 Circulations
por: Miller, Wayne L.
Publicado: (2022)

Postdischarge Environment Following Heart Failure Hospitalization: Expanding the View of Hospital Readmission
por: Hersh, Andrew M., et al.
Publicado: (2013)

Impact of Interatrial Shunts on Invasive Hemodynamics and Exercise Tolerance in Patients With Heart Failure
por: Griffin, Jan M., et al.
Publicado: (2020)

SGLT2 inhibition to address the unmet needs in diabetic nephropathy
por: Barutta, Federica, et al.
Publicado: (2019)

SGLT-2 Inhibitors in Heart Failure: A Review of Current Evidence
por: Talha, Khawaja M., et al.
Publicado: (2023)

Clonal Hematopoiesis of Indeterminate Potential From a Heart Failure Specialist's Point of View
por: Sikking, Maurits A., et al.
Publicado: (2023)

Therapeutic Challenges and Emerging Treatment Targets for Pulmonary Hypertension in Left Heart Disease
por: Lteif, Christelle, et al.
Publicado: (2021)

Neurohormonal Regulation of I(Ks) in Heart Failure: Implications for Ventricular Arrhythmogenesis and Sudden Cardiac Death
por: Shugg, Tyler, et al.
Publicado: (2020)

Epidemiology and Clinical Features of Heart Failure with Preserved Ejection Fraction
por: Teramoto, Kanako, et al.
Publicado: (2022)

Cardiorenal Nexus: A Review With Focus on Combined Chronic Heart and Kidney Failure, and Insights From Recent Clinical Trials
por: McCullough, Peter A., et al.
Publicado: (2022)

Therapeutic Management of Anomalous Coronary Arteries Originating From the Opposite Sinus of Valsalva: Current Evidence, Proposed Approach, and the Unknowing
por: Bigler, Marius Reto, et al.
Publicado: (2022)

Are the Cardiorenal Benefits of SGLT2 Inhibitors Due to Inhibition of the Sympathetic Nervous System?
por: Verma, Subodh
Publicado: (2020)

Genomic, Proteomic, and Metabolic Comparisons of Small Animal Models of Heart Failure With Preserved Ejection Fraction: A Tale of Mice, Rats, and Cats
por: Smith, Alex N., et al.
Publicado: (2022)

Contemporary Management of Atrial Fibrillation: What Can Clinical Registries Tell Us About Stroke Prevention and Current Therapeutic Approaches?
por: Lip, Gregory Y. H., et al.
Publicado: (2014)

Current Utilization Trends of SGLT-2 Inhibitors in Type 2 Diabetics With Heart Failure
por: Dhillon, Puneet, et al.
Publicado: (2021)

SGLT2 Inhibitors and Ketone Metabolism in Heart Failure
por: Saucedo-Orozco, Huitzilihuitl, et al.
Publicado: (2022)

Tuberculosis and the Heart
por: López‐López, José Patricio, et al.
Publicado: (2021)

Heart Failure and Multimorbidity in Asia
por: Ang, Nathalie, et al.
Publicado: (2023)

Cannabinoids, the Heart of the Matter
por: Alfulaij, Naghum, et al.
Publicado: (2018)

The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective
por: Muscoli, Saverio, et al.
Publicado: (2022)

Cybersecurity: The need for data and patient safety with cardiac implantable electronic devices
por: Das, Subrat, et al.
Publicado: (2021)

Epigenetics in Congenital Heart Disease
por: Wang, Guanglei, et al.
Publicado: (2022)

Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors
por: Verma, Subodh, et al.
Publicado: (2018)

2002 White Paper on Pharmacy Technicians: Needed Changes Can No Longer Wait
por: Tice, Linwood
Publicado: (2003)

Summary Report of the Arthritis Foundation and the American Orthopaedic Foot & Ankle Society’s Symposium on Targets for Osteoarthritis Research: Part 1: Epidemiology, Pathophysiology, and Current Imaging Approaches
por: Kim, Jason S., et al.
Publicado: (2022)

Benefits of SGLT2 Inhibitor: Preventing Heart Failure and Beyond
por: Kim, Yong Sook, et al.
Publicado: (2019)

SGLT2 inhibitors in heart failure with reduced ejection fraction
por: Das, Uday Sankar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_b2kvpfm4ore0k2b3phef80qv25